Update shared on 25 Nov 2025
Fair value Decreased 0.067%Analysts have slightly lowered their price target for Stevanato Group, adjusting the fair value from $28.80 to $28.78 based on minor updates to growth and profitability expectations.
What's in the News
- Stevanato Group S.p.A. maintained its revenue guidance for 2025, expecting revenues in the range of €1.160 billion to €1.190 billion (Key Developments).
- The company announced a significant expansion of its drug delivery system manufacturing capacity by adding over 2,500 square meters of production space in Bad Oeynhausen, Germany. The expansion includes the installation of an ISO 8 cleanroom for injection molding and automated assembly (Key Developments).
- This expansion strengthens Stevanato Group's global position by supporting robust supply-chain integration for pharma and biotech partners and advancing the production of devices such as the Aidaptus autoinjector and Alina pen injector platforms (Key Developments).
Valuation Changes
- Fair Value Estimate: decreased slightly from $28.80 to $28.78 per share.
- Discount Rate: increased modestly from 10.73% to 10.78%.
- Revenue Growth: decreased from 9.45% to 9.38%.
- Net Profit Margin: increased from 16.40% to 16.69%.
- Future P/E Ratio: declined marginally from 36.69x to 36.26x.
Have other thoughts on Stevanato Group?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.